An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
Mariam Jamal‐Hanjani(CRUK Lung Cancer Centre of Excellence), Martin Förster, Fiona Thistlethwaite(The Christie NHS Foundation Trust), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Yvonne Summers(The Christie NHS Foundation Trust), Leila Khoja(AstraZeneca (United Kingdom)), Kim Orchard(University of Namur), Jennifer Allison(The Christie NHS Foundation Trust), Shreenal Patel, Christian H. Ottensmeier(Clatterbridge Cancer Centre NHS Foundation Trust), Judith Cave(University College London), Jane Robertson(Cancer Research UK), Michael Grant, Karl S. Peggs(Royal London Hospital), Alastair Greystoke(Newcastle University)
Cited by 5
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k